updat estim revenu exhibit
cc cc sell day sd adj report
cc cc sd adj report compar consensu
report ep estim prior vs
consensu model gm/om/tax prior
updat estim fy lower revenu
estim exhibit cc cc sd adj report
cc cc sd adj report compar
consensu report in-lin compani
guidanc rang decreas revenu mostli due
neg fx impact slightli off-set higher hip
 knee fy ep estim prior
vs consensu guidanc rang assum
gm/om/tax prior model
presum ww hip knee market growth approxim seen
hip knee currenc sell day adjust
north campu suppli restor expect begin
fall-out recent regard suppli avail time resolut
fda warn letter previous will/ha ceo met
fda complianc divis convey commit qualiti price/
volum share trend global hip/kne market inclus
prospect regain lost share new product persona partial
revis knee cement-less knee major joint robot key
offer schedul full launch abil regain momentum
spine given new leadership ldr rosa robot updat regard
portfolio manag potenti futur divest low-growth
busi segment dental color margin progress expect
inclus potenti reduc outsourc autom
system place north campu
valuat risk rel valuat model regress year
anticip top-lin trajectori zbh case suggest rel forward
multipl continu pg
tr target
target price will stretch regard rel forward multipl award
time forward ep base likelihood improv oper
perform risk includ execut misstep inclus failur remedi product
suppli shortfal under-perform vs end market perhap sluggish anticip
earn call juli et dial-in id
page
page
page
page
million except per share interest expens inc analysisgross cmf sale sale cc/sd/divest sale inc inc
zimmer lead player musculoskelet devic segment player hip
ww share knee meaning presenc musculoskelet categori dental
cmf/thorac surgic sport medicin extrem trauma
spine ex-ldrh spun parent august headquart
believ full product suppli key new product introduct inclus partial knee
cement-less knee new revis knee rosa orthoped robot appear us
repres seriou effort compani show increas sale momentum
like attain consist growth also model modicum leverag
improv bp level beyond point compani undoubtedli
reconfigur portfolio lessen depend low singl digit major joint market seek
aggress leverag proven commerci organ non-major joint product somewhat
problemat latter regard fact unencumb wont begin substanti
due debt servic although sale dental could help albeit measur ebitda cost
valuat risk
rel valuat model regress year anticip top-lin trajectori zbh case
suggest rel forward multipl target price will stretch
regard rel forward multipl award time forward ep base
likelihood improv oper perform risk includ execut misstep inclus
failur remedi product suppli shortfal under-perform vs end market perhap
sluggish anticip major joint market
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
